Before accessing the site, please choose from the following options.
Co-Head of Tactical Value Investing | 33 years industry experience
Co-Head of Tactical Value Investing 33 years industry experience
Our team's structuring expertise, complemented by Morgan Stanley's broad capabilities and transaction knowledge, enable us to address a company’s unique capital needs or idiosyncratic risks.
Thomas Cahill is a Managing Director of Morgan Stanley and Co-Head of Morgan Stanley’s Tactical Value Investing Team (MSTV). Mr. Cahill joined Morgan Stanley in 1990. Prior to joining MSTV in January 2017, he was the Global Head of the Asset Finance Group, which consists of all credit based structured finance products within the Global Capital Markets (GCM) platform. Previously, Mr. Cahill was the head of the Debt Products Group of GCM, and had responsibility for Aircraft Finance, Equipment Finance, Liability Management, Structured Corporates and Private Placements. During his career, he has focused on the area of Equipment Finance and is a recognized leader in the development, structuring, and execution of secured debt transactions involving aircraft, locomotives, rolling stock, ships, power generation facilities, cell towers and real estate. Mr. Cahill was a founding member of Morgan Stanley’s Aircraft Finance effort and the inventor of Enhanced Equipment Trust Certificates (EETCs). He was also the creator of PhaRMASM, a product designed to monetize drug royalty streams, as well as the designer of the current industry standard platform of cell tower securitizations. Mr. Cahill was a member of the Global Capital Markets Management Committee and the Investment Banking Division Management Committee. He graduated with highest honors from Lehigh University in 1985 with a B.S. in Engineering Physics, with high honors with a B.A. in Mathematics in 1986 and was elected to Phi Beta Kappa and Tau Beta Pi honor societies. In 1990 Mr. Cahill received an M.B.A. from the Institut Européen d’Administration des Affaires (INSEAD). He is a member of the Advisory Council of the Morgan Stanley Children’s Hospital.
The information on this page is for informational purposes only. It is intended for the benefit of third party issuers and those seeking information about alternatives investment strategies. The information contained herein does not constitute and should not be construed as an offering of advisory services or an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction in which such offer or solicitation, purchase or sale would be unlawful under the securities, insurance or other laws of such jurisdiction.
All investing involves risks, including a loss of principal. Alternative investments are speculative and involve a high degree of risk. These investments are designed for investors who understand and are willing to accept these risks. Performance may be volatile, and an investor could lose all or a substantial portion of his or her investment.
Please refer to the strategy detail page for important information on the strategy, including additional risk considerations.